Mechanisms of Bone Anabolism Regulated by Statins.

Bioscience Reports (Impact Factor: 2.85). 07/2012; 32(Pt 6). DOI: 10.1042/BSR20110118
Source: PubMed

ABSTRACT Osteoporosis is a common disease in the elderly population. The progress of this disease results in the reduction of bone mass and can increase the incidence of fractures. Drugs presently used clinically can block the aggravation of this disease. However, these drugs cannot increase the bone mass and may result in certain side effects. Statins, also known as 3-hydroxy-3-methyl-glutarylcoenzyme A (HMG-CoA) reductase inhibitors, are widely prescribed for cardiovascular disease for decades. Nonetheless, accumulating studies demonstrate that statins exert bone anabolic effect and may be helpful for the treatment of osteoporosis. Abundant of experiments have analyzed the mechanisms of bone anabolism regulated by statins. In the present paper, we review the mechanisms of promoting osteogenesis, suppressing osteoblast apoptosis and inhibiting osteoclastogenesis.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Statins have a beneficial effect on bone mineral density (BMD) and lean mass in some studies of HIV-uninfected adults; however, this has never been investigated in the setting of HIV infection.
    AIDS (London, England) 11/2014; 29(2). DOI:10.1097/QAD.0000000000000526 · 6.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Statins competitively inhibit hepatic 3-hydroxy-3-methylglutaryl-coenzyme A reductase, resulting in reduced plasma total and low-density lipo- protein cholesterol levels. Recently, it has been shown that statins exert additional ‘pleiotropic’ effects by increasing expression levels of the membrane water channels aquaporin 2 (AQP2). AQP2 is localized mainly in the kidney and plays a critical role in determining cellular water con- tent. This additional effect is independent of cholesterol homoeostasis, and depends on depletion of mevalonate-derived intermediates of sterol synthetic pathways, i.e. farnesylpyrophosphate and geranylgeranylpyrophosphate. By up-regulating the expression levels of AQP2, statins increase water reabsorption by the kidney, thus opening up a new avenue in treating patients with nephrogenic diabetes insipidus (NDI), a hereditary disease that yet lacks high-powered and limited side effects therapy. Aspects related to water balance determined by AQP2 in the kidney, as well as standard and novel therapeutic strategies of NDI are discussed.
    Journal of Cellular and Molecular Medicine 11/2014; in press:1-19. DOI:10.1111/jcmm.12422 · 3.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context Tooth extraction and periodontal disease are both common clinical situations associated with alveolar bone loss. Purpose The objective was to analyze the reported results of in vivo studies investigating the effectiveness of statins to reduce alveolar bone resorption. Material and methods Systematic electronic search of the MEDLINE-Pubmed database. Results A total of 21 studies satisfied the inclusion criteria. This review showed that the use of statins reduced significantly alveolar bone resorption observed during periodontal disease and after tooth extraction. Oral administration was effective using high statin concentrations although local administration using a biodegradable carrier was effective with lower concentrations. It was recently reported that statins were effective to reduce alveolar bone loss as an adjunct to SRP in several clinical trials. Further studies are needed to confirm these promising results.
    Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 01/2014; DOI:10.1016/j.oooo.2014.09.030 · 1.46 Impact Factor


Available from